Further analyses showed that the initial level of PSA (p = 0.004), the intermittent administration of ADT (0.045), and the number of prescribed drugs (p = 0.006) during docetaxel ADT therapy (0.045) had a significant influence on increasing the MAI score and, thus, elevating the term of inappropriate prescribing in prostate cancer patients. The gene discussed is KLK3; the disease is prostate cancer.